DURECT Corp
DRRX1.910USD
0.000
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
59.29MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über DURECT Corp Unternehmen
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.
DURECT Corp Informationen
BörsenkürzelDRRX
Name des UnternehmensDURECT Corp
IPO-datumSep 28, 2000
CEOMr. James E. Brown
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeSep 28
Addresse10240 Bubb Road
StadtCUPERTINO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl95014
Telefon14087771417
Websitehttps://www.durect.com/
BörsenkürzelDRRX
IPO-datumSep 28, 2000
CEOMr. James E. Brown
Führungskräfte von DURECT Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ashley Robinson
Mr. Ashley Robinson
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Timothy M. Papp
Mr. Timothy M. Papp
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. James E. Brown
Mr. James E. Brown
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Norman L. Sussman, M.D.
Dr. Norman L. Sussman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ashley Robinson
Mr. Ashley Robinson
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Timothy M. Papp
Mr. Timothy M. Papp
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. James E. Brown
Mr. James E. Brown
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Norman L. Sussman, M.D.
Dr. Norman L. Sussman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Europe
324.00K
72.48%
Other
63.00K
14.09%
United States
60.00K
13.42%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Sep 14
Aktualisiert: Sun, Sep 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Asen (Scott R.)
10.31%
Richmond Brothers, Inc.
4.68%
Ingalls & Snyder LLC (Asset Management)
4.35%
The Vanguard Group, Inc.
4.08%
Dalton Investments, Inc.
2.40%
Andere
74.18%
Aktionäre
Aktionäre
Anteil
Asen (Scott R.)
10.31%
Richmond Brothers, Inc.
4.68%
Ingalls & Snyder LLC (Asset Management)
4.35%
The Vanguard Group, Inc.
4.08%
Dalton Investments, Inc.
2.40%
Andere
74.18%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
12.51%
Individual Investor
11.00%
Investment Advisor/Hedge Fund
9.79%
Hedge Fund
0.60%
Research Firm
0.27%
Venture Capital
0.04%
Andere
65.80%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
108
10.77M
34.70%
-3.79M
2025Q1
115
10.47M
33.77%
-4.69M
2024Q4
121
10.25M
33.03%
-6.31M
2024Q3
136
10.05M
32.37%
-5.85M
2024Q2
154
9.42M
30.55%
-4.23M
2024Q1
183
8.84M
28.67%
-5.03M
2023Q4
192
7.39M
25.17%
-5.35M
2023Q3
219
10.25M
37.42%
-1.75M
2023Q2
226
9.55M
39.01%
-2.60M
2023Q1
233
10.65M
43.65%
-399.75K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Asen (Scott R.)
--
0%
+122.53K
-100.00%
Richmond Brothers, Inc.
--
0%
+107.33K
-100.00%
Ingalls & Snyder LLC (Asset Management)
--
0%
+14.64K
-100.00%
The Vanguard Group, Inc.
--
0%
--
--
Dalton Investments, Inc.
--
0%
+232.69K
-100.00%
Gagnon Securities LLC
--
0%
--
--
Geode Capital Management, L.L.C.
--
0%
-3.06K
-100.00%
Beirne Wealth Consulting Services, LLC
--
0%
+17.80K
-100.00%
Montchanin Asset Management, LLC
--
0%
+6.09K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
--
--
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Datum
Art
Verhältnis
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
